Mantomed (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors. By blocking the receptor’s ion channel, it reduces calcium overload that can lead to neuronal injury, while still allowing normal neurotransmission necessary for learning and memory.

The dosage of Mantomed is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Physicians typically start with a low dose and titrate upward as needed.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Mantomed product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mantomed (memantine) belongs to the NMDA‑receptor antagonist class, whereas drugs such as donepezil or rivastigmine are acetylcholinesterase inhibitors. Memantine is typically used for moderate‑to‑severe disease and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Mantomed should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Mantomed is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse events include seizures, severe allergic reactions such as anaphylaxis, hallucinations, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience any of these symptoms while taking the medication.

Mantomed is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, unless a clinician determines the benefits outweigh the risks.